BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, January 2, 2026
See today's BioWorld
Home
» Wuxi delivers a solid first quarter despite China's macroeconomic woes
To read the full story,
subscribe
or
sign in
.
Wuxi delivers a solid first quarter despite China's macroeconomic woes
May 16, 2014
By
Cornelia Zou
HONG KONG – Powered by sales of biologics and other pharmaceutical products, Wuxi Pharmatech Inc. posted strong first quarter results hurt only by a depreciation in the Chinese RMB.
BioWorld
